The present disclosure concerns compounds of formula (I) and pharmaceutically acceptable salts, hydrates, solvates, pharmaceutically acceptable derivatives, pro-drugs, tautomers and/or isomers thereof. The disclosure also relates to processes for the preparation of compounds according to formula (I), pharmaceutical or veterinary compositions containing such compounds or methods of treatment and/or prophylaxis of a condition or symptom that is inhibited, reduced or alleviated by opioid receptor activation.
1
本公开涉及式(I)的化合物及其药学上可接受的盐、
水合物、溶剂物、药学上可接受的衍
生物、前药、互变异构体和/或同分异构体。该公开还涉及根据式(I)制备化合物的方法,包含这样的化合物的药物或兽药组合物或通过阿片受体激活抑制、减少或缓解症状或状态的治疗和/或预防方法。